PURPOSE: The tumor mRNA expression levels of mammaglobin, a novel breast-specific and breast cancer-associated marker, were correlated with disease outcome in 280 patients with primary breast cancer. PATIENTS AND METHODS: Mammaglobin expression levels were assessed by quantitative reverse transcriptase polymerase chain reaction in frozen tumor tissue from breast cancer patients with a median age of 60 years (range, 30 to 88 years) and a median follow-up of 85 months (range, 2 to 169 months). RESULTS: High expression levels were associated with low-grade tumors (P =.018), with positive estrogen and progesterone receptor status (P <.001), and postmenopausal status (P =.010). In the analysis of all patients, low tumor mammaglobin expression levels predicted an early relapse both in Cox univariate (hazard ratio [HR], 0.52; 95% CI, 0.34 to 0.79; P =.002) and multivariate regression analyses corrected for the traditional prognostic factors (HR, 0.55; 95% CI, 0.35 to 0.88; P =.012). The association of mammaglobin expression with the rate of relapse was particularly favorable in patients who received adjuvant tamoxifen treatment (HR, 0.35; 95% CI, 0.17 to 0.71; P =.004). CONCLUSION: These results demonstrate that the assessment of the tumor mRNA expression level of the breast-specific protein mammaglobin could be useful to stratify patients for individual adjuvant treatment strategies.
PURPOSE: The tumor mRNA expression levels of mammaglobin, a novel breast-specific and breast cancer-associated marker, were correlated with disease outcome in 280 patients with primary breast cancer. PATIENTS AND METHODS: Mammaglobin expression levels were assessed by quantitative reverse transcriptase polymerase chain reaction in frozen tumor tissue from breast cancerpatients with a median age of 60 years (range, 30 to 88 years) and a median follow-up of 85 months (range, 2 to 169 months). RESULTS: High expression levels were associated with low-grade tumors (P =.018), with positive estrogen and progesterone receptor status (P <.001), and postmenopausal status (P =.010). In the analysis of all patients, low tumor mammaglobin expression levels predicted an early relapse both in Cox univariate (hazard ratio [HR], 0.52; 95% CI, 0.34 to 0.79; P =.002) and multivariate regression analyses corrected for the traditional prognostic factors (HR, 0.55; 95% CI, 0.35 to 0.88; P =.012). The association of mammaglobin expression with the rate of relapse was particularly favorable in patients who received adjuvant tamoxifen treatment (HR, 0.35; 95% CI, 0.17 to 0.71; P =.004). CONCLUSION: These results demonstrate that the assessment of the tumor mRNA expression level of the breast-specific protein mammaglobin could be useful to stratify patients for individual adjuvant treatment strategies.
Authors: Maria Kabisch; Justo Lorenzo Bermejo; Thomas Dünnebier; Shibo Ying; Kyriaki Michailidou; Manjeet K Bolla; Qin Wang; Joe Dennis; Mitul Shah; Barbara J Perkins; Kamila Czene; Hatef Darabi; Mikael Eriksson; Stig E Bojesen; Børge G Nordestgaard; Sune F Nielsen; Henrik Flyger; Diether Lambrechts; Patrick Neven; Stephanie Peeters; Caroline Weltens; Fergus J Couch; Janet E Olson; Xianshu Wang; Kristen Purrington; Jenny Chang-Claude; Anja Rudolph; Petra Seibold; Dieter Flesch-Janys; Julian Peto; Isabel dos-Santos-Silva; Nichola Johnson; Olivia Fletcher; Heli Nevanlinna; Taru A Muranen; Kristiina Aittomäki; Carl Blomqvist; Marjanka K Schmidt; Annegien Broeks; Sten Cornelissen; Frans B L Hogervorst; Jingmei Li; Judith S Brand; Keith Humphreys; Pascal Guénel; Thérèse Truong; Florence Menegaux; Marie Sanchez; Barbara Burwinkel; Frederik Marmé; Rongxi Yang; Peter Bugert; Anna González-Neira; Javier Benitez; M Pilar Zamora; Jose I Arias Perez; Angela Cox; Simon S Cross; Malcolm W R Reed; Irene L Andrulis; Julia A Knight; Gord Glendon; Sandrine Tchatchou; Elinor J Sawyer; Ian Tomlinson; Michael J Kerin; Nicola Miller; Christopher A Haiman; Fredrick Schumacher; Brian E Henderson; Loic Le Marchand; Annika Lindblom; Sara Margolin; Maartje J Hooning; Antoinette Hollestelle; Mieke Kriege; Linetta B Koppert; John L Hopper; Melissa C Southey; Helen Tsimiklis; Carmel Apicella; Seth Slettedahl; Amanda E Toland; Celine Vachon; Drakoulis Yannoukakos; Graham G Giles; Roger L Milne; Catriona McLean; Peter A Fasching; Matthias Ruebner; Arif B Ekici; Matthias W Beckmann; Hermann Brenner; Aida K Dieffenbach; Volker Arndt; Christa Stegmaier; Alan Ashworth; Nicholas Orr; Minouk J Schoemaker; Anthony Swerdlow; Montserrat García-Closas; Jonine Figueroa; Stephen J Chanock; Jolanta Lissowska; Mark S Goldberg; France Labrèche; Martine Dumont; Robert Winqvist; Katri Pylkäs; Arja Jukkola-Vuorinen; Mervi Grip; Hiltrud Brauch; Thomas Brüning; Yon-Dschun Ko; Paolo Radice; Paolo Peterlongo; Giulietta Scuvera; Stefano Fortuzzi; Natalia Bogdanova; Thilo Dörk; Arto Mannermaa; Vesa Kataja; Veli-Matti Kosma; Jaana M Hartikainen; Peter Devilee; Robert A E M Tollenaar; Caroline Seynaeve; Christi J Van Asperen; Anna Jakubowska; Jan Lubinski; Katarzyna Jaworska-Bieniek; Katarzyna Durda; Wei Zheng; Martha J Shrubsole; Qiuyin Cai; Diana Torres; Hoda Anton-Culver; Vessela Kristensen; François Bacot; Daniel C Tessier; Daniel Vincent; Craig Luccarini; Caroline Baynes; Shahana Ahmed; Mel Maranian; Jacques Simard; Georgia Chenevix-Trench; Per Hall; Paul D P Pharoah; Alison M Dunning; Douglas F Easton; Ute Hamann Journal: Carcinogenesis Date: 2015-01-13 Impact factor: 4.944
Authors: Monica M Reinholz; Kathleen A Kitzmann; Kathleen Tenner; David Hillman; Amylou C Dueck; Timothy J Hobday; Donald W Northfelt; Alvaro Moreno-Aspitia; Vivek Roy; Betsy LaPlant; Jake B Allred; Philip J Stella; Wilma L Lingle; Edith A Perez Journal: Clin Cancer Res Date: 2011-10-05 Impact factor: 12.531
Authors: Sylvie M Noordermeer; Marloes Wennemers; Saskia M Bergevoet; Adrian van der Heijden; Evelyn Tönnissen; Fred C G J Sweep; Joop H Jansen; Paul N Span; Bert A van der Reijden Journal: Breast Cancer Res Treat Date: 2012-06-16 Impact factor: 4.872
Authors: M H W Starmans; N G Lieuwes; P N Span; S Haider; L Dubois; F Nguyen; H W van Laarhoven; F C G J Sweep; B G Wouters; P C Boutros; P Lambin Journal: Br J Cancer Date: 2012-06-21 Impact factor: 7.640
Authors: Marloes Wennemers; Johan Bussink; Blanca Scheijen; Iris D Nagtegaal; Hanneke W M van Laarhoven; James A Raleigh; Mahesh A Varia; Joop J T M Heuvel; Kasper M Rouschop; Fred C G J Sweep; Paul N Span Journal: Breast Cancer Res Date: 2011-08-24 Impact factor: 6.466
Authors: Brunna Dos Anjos Pultz; Felipe Andrés Cordero da Luz; Paulo Rogério de Faria; Ana Paula Lima Oliveira; Rogério Agenor de Araújo; Marcelo José Barbosa Silva Journal: J Cancer Date: 2014-07-04 Impact factor: 4.207